Cerulean Pharma Inc. (NASDAQ:DARE) shares hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $3.11 and last traded at $3.11, with a volume of 75,348 shares. The stock had previously closed at $3.40.
Separately, ValuEngine cut shares of Cerulean Pharma from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.55.
The stock has a 50-day moving average of $4.87 and a 200 day moving average of $7.60. The stock’s market cap is $8.01 million.
COPYRIGHT VIOLATION WARNING: This story was first published by BNB Daily and is the sole property of of BNB Daily. If you are viewing this story on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/cerulean-pharma-inc-nasdaqdare-reaches-new-12-month-low-at-3-11-updated-updated.html.
Cerulean Pharma Company Profile
Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.
Receive News & Ratings for Cerulean Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerulean Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.